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“There is something in age that ever, even in 
its own despite, must be venerable, must create 
respect—and to have it ill treated, is to me worse, 
more cruel and wicked than anything on earth.” 
—Frances Burney, 1768
O
ne of the noblest uses 
of epidemiology is the 
investigation of sources 
of inequalities in health outcomes. 
Research on prognostic factors of 
cancer survival fulﬁ  lls this mission 
and is part of the expanded purview 
of cancer epidemiology. This type 
of research is best done in countries 
that are served by established tumour 
registries with efﬁ  cient linkage to 
administrative databases that include 
patients’ records from screening 
programs and hospital data on 
diagnoses and clinical outcomes. 
Such countries enjoy the beneﬁ  ts of a 
cancer surveillance system that covers 
the entire spectrum from primary to 
tertiary cancer prevention.
In this issue of PLoS Medicine, Eaker 
and colleagues describe a simple 
yet long-ranging observational study 
of breast cancer survival that uses 
Sweden’s much-admired cancer 
surveillance system [1]. The authors 
conducted a population-based study 
that encompassed an entire health 
region to test the hypothesis that 
possible differences in diagnosis and 
management of breast cancer in older 
women would have an impact on 
survival. They studied more than 9,000 
patients aged 50–84 years with breast 
cancer diagnosed between 1992 and 
2002, calculating 5-year relative survival 
and related statistics that contrasted 
women aged 70–84 years with those 
who were 50–69 years at the time of 
diagnosis. Overall, the 5-year relative 
survival was 13% lower for those aged 
70–84 years as compared with patients 
50–69 years of age. The disparity in 
survival was greatest for those with 
disease stages IIB–III and for those 
whose tumour was not staged. 
How Can the Age-Related 
Prognostic Effect Be Explained?
Figure 1 shows a schematic of the 
underlying prognostic pathway 
model that was entertained by the 
authors. Having established that 
the distal, remote prognostic effect 
due to advanced age was real, they 
hypothesized that the association 
would be mediated largely by the 
intermediate variables shown in the 
model. The authors serendipitously 
explored the heterogeneity in their 
dataset that originated from the 
existence in their chosen health-
care region of counties with more 
liberal policies that extend screening 
opportunity to women outside of 
the 50–69 year age range that was 
adopted by the Swedish health system. 
Measures of disease burden (tumour 
size and lymph node involvement) and 
markers of histological severity and 
hormonal responsiveness were available 
to the authors and formed one set 
of covariates, which they controlled 
for via stratiﬁ  cation or regression 
model adjustment. Management and 
treatment variables, such as type and 
intent of surgery, radiation treatment, 
and chemotherapy (including 
tamoxifen use) were available as 
well. The authors used local clinical 
guidelines to judge whether or not 
Perspectives
March 2006  |  Volume 3  |  Issue 3  |  e48
Epidemiology As a Tool to Reveal Inequalities 
in Breast Cancer Care
Eduardo L. Franco
Citation: Franco EL (2006) Epidemiology as a tool to 
reveal inequalities in breast cancer care. PLoS Med 
3(3): e48. 
Copyright: © 2006 Eduardo L. Franco. This is an 
open-access article distributed under the terms 
of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original 
author and source are credited.
Eduardo L. Franco is James McGill Professor of 
Epidemiology and Oncology, and Director, Division 
of Cancer Epidemiology, McGill University, Montreal, 
Canada. E-mail: eduardo.franco@mcgill.ca
Competing Interests: EF is on the editorial board of 
PLoS Medicine. He declares that he has no competing 
interests.
DOI: 10.1371/journal.pmed.0030048
DOI: 10.1371/journal.pmed.0030048.g001
Figure 1. Model of Prognostic Pathway That Explains the Lower Breast Cancer Survival 
Expectation in Women Older than 70 Years
The remote, distal prognostic effect is mediated via three intermediate, proximal determinants of 
clinical outcome. Ideally, only co-morbidity and other age-related factors that are beyond the reach 
of modern health care should be operative. Unfortunately, decreased access to screening and to 
optimal treatment and management tend to further increase the disparity in survival between 
young and old women with breast cancer.
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the quality and quantity of treatment 
received via the three modalities were 
considered adequate and consonant 
with standard practices. They 
computed a low-treatment activity 
index speciﬁ  c for each stage grouping 
that subsumed the overall extent of 
suboptimal management and treatment 
decisions that may have affected the 
patient’s prognosis (the central factor 
in Figure 1). 
To test the empirical validity of 
the model in Figure 1, they ﬁ  rst 
demonstrated that the top connecting 
relations (old age   advanced disease; 
old age   undertreatment) were real. 
Older women had fewer instances of 
screening-detected cancers, had larger 
tumours, had fewer nodes examined, 
and underwent radiotherapy or 
chemotherapy less frequently than 
younger women. Final proof that these 
imbalances in disease burden and 
treatment decisions were the actual 
mediators of the disadvantage in 
prognosis requires that the regression 
models relating age and relative 
mortality incorporate adjustment for 
diagnostic and tumour characteristics 
and treatment. If the remote 
prognostic relation is truly mediated by 
the latter variables, then the magnitude 
of the statistical effect (measured as 
relative excess mortality contrasting 
patients 70–84 years with those 
50–69 years) would be diminished 
upon adjustment for the putatively 
intermediate covariates. 
In fact, this is what the authors 
observed: the crude excess 
proportional mortality, which ranged 
between 43% and 83% for stages IIB, 
III, and unstaged patients, decreased 
to −9% to 26% after full adjustment 
for the intermediate variables (shown 
in Table 5 of [1]). Moreover, the 
statistical signiﬁ  cance of the observed 
excess mortality disappeared after 
adjustment. In conclusion, the authors 
had elegantly demonstrated through 
clever use of regression modeling 
and mediated analysis [2,3] of breast 
cancer surveillance data that most of 
the original survival disadvantage was 
attributable to the biases against older 
women in access to health care.
Lessons from a Scientiﬁ  c 
Standpoint
Unlike basic science disciplines, 
where the discovery process has more 
external cues, the reward for the 
pursuit of epidemiological ﬁ  ndings 
exists exclusively from an intellectual 
perspective. The “eureka” factor in 
Eaker et al.’s study [1] comes from the 
simple realization that the adjusted 
estimates of excess mortality were 
lower than those seen in the univariate 
models, which implies that the original 
crude estimate reﬂ  ected mostly the 
prognostic effect of the intermediate 
factors shown in Figure 1. The 
mediated analysis that they conducted 
is akin to the true experimentation and 
probing that is typical of laboratory-
based research [3]. They formulated 
a hypothesis and veriﬁ  ed it with 
crisp deductive logic by probing 
relations in an underlying model. The 
relevance of the conclusion cannot be 
overemphasized: had we eliminated 
the age-related systemic disparities in 
access to screening and cancer care, 
the substantial survival disadvantage 
of older breast cancer patients would 
have disappeared completely. As an 
epidemiologist, I cannot ﬁ  nd a better 
use for an observational study.
Lessons from a Public-Health 
Perspective
Eaker and colleagues conducted 
their observational study in a Swedish 
population, a country that enjoys one 
of the most progressive health-care 
systems in the world. Cancer screening 
is the right of all citizens, and ability to 
pay is not a determinant of access to 
oncological care in Sweden. Yet, local 
variations in practice do exist, largely 
due to policy decisions stemming from 
how different Swedish jurisdictions 
interpret the evidence base on 
the cost-effectiveness of screening 
and treatment modalities. Cancer 
screening, management, and treatment 
compete for funds with other pressing 
health-care needs.
Sweden does not come to mind when 
one ponders the typical dilemma of 
making funding decisions to prioritize 
health-care expenditures. Nevertheless, 
countries that can afford to sustain 
central planning and policy making 
in cancer control tend to favour 
providing the greatest beneﬁ  t for 
the ones at highest risk and for the 
lowest possible cost. Given the low 
remaining life expectancy among the 
elderly and nearly complete exclusion 
of older patients from clinical trials, 
most countries have little incentive to 
implement health-promotion policies 
that do not overtly neglect older 
people. As the authors so poignantly 
concluded, this “is a very distressing 
ﬁ  nding, since around 30% of all breast 
cancer patients are above the age of 
70.” The question that is left for all of 
us—not only those with careers devoted 
to cancer control—to answer is: to 
what extent do we as a society want to 
continue to assign lesser importance to 
our elderly when formulating health 
policies and research priorities?  
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